8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Feb 19, 2026·SEC
Bio-Rad Laboratories, Inc.(BIO)Earnings, Financials & Key Ratios
BIO•NYSE
10.1× P/E·Price updated Jun 19, 2026
AboutBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.Show more
- Revenue$2.58B+0.7%
- EBITDA$476M+13.1%
- Net Income$760M+141.2%
- EPS (Diluted)27.87+142.6%
- Gross Margin52.01%-3.2%
- EBITDA Margin18.42%+12.4%
- Operating Margin10.47%
- Net Margin29.42%+140.9%
- ROE10.84%+145.0%
BIO Key Insights
Bio-Rad Laboratories, Inc. (BIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 3.3% through buybacks
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Profits declining 27.6% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BIO Price & Volume
Bio-Rad Laboratories, Inc. (BIO) stock price & volume — 10-year historical chart
Loading chart...
BIO Growth Metrics
Bio-Rad Laboratories, Inc. (BIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.49%
5 Years0.29%
3 Years-2.68%
TTM1.92%
Profit CAGR
10 Years20.99%
5 Years-27.58%
3 Years-
TTM107.8%
EPS CAGR
10 Years22.34%
5 Years-26.07%
3 Years-
TTM107.97%
Return on Capital
10 Years2.53%
5 Years2.96%
3 Years2.73%
Last Year2.85%
BIO Recent Earnings
Bio-Rad Laboratories, Inc. (BIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.89-5.0%
$1.99
Rev
$592M+0.4%
$590M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$2.51-2.3%
$2.57
Rev
$693M+0.6%
$689M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$2.26-1.7%
$2.30
Rev
$653M-6.0%
$695M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$2.61+35.2%
$1.93
Rev
$652M+2.8%
$634M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.89vs $1.99-5.0% | $592Mvs $590M+0.4% |
| Q1 2026 | Feb 12, 2026 | $2.51vs $2.57-2.3% | $693Mvs $689M+0.6% |
| Q4 2025 | Oct 29, 2025 | $2.26vs $2.30-1.7% | $653Mvs $695M-6.0% |
| Q3 2025 | Jul 31, 2025 | $2.61vs $1.93+35.2% | $652Mvs $634M+2.8% |
Based on last 12 quarters of dataView full earnings history →
BIO Peer Comparison
Bio-Rad Laboratories, Inc. (BIO) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 | |
 BRKR | 8.71B | 57.23 | -381.53 | 2.08% | -0.34% | -0.5% | 0.81 | |
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 | |
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 | |
 IDXX | 44.64B | 562.09 | 42.97 | 10.42% | 24.63% | 70.87% | 0.67 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 QGEN | 7.61B | 36.95 | 18.11 | 5.65% | 20.33% | 11.85% | 0.44 |
Compare BIO vs Peers
Bio-Rad Laboratories, Inc. (BIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIO Income Statement
Bio-Rad Laboratories, Inc. (BIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.16B | 2.29B | 2.31B | 2.55B | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B | 2.59B |
Revenue Growth % | 4.45% | 6.02% | 0.94% | 10.12% | 14.81% | -4.12% | -4.67% | -3.92% | 0.65% | 1.92% |
Cost of Goods Sold | 972.75M | 1.07B | 1.05B | 1.11B | 1.28B | 1.23B | 1.24B | 1.19B | 1.24B | 1.25B |
COGS % of Revenue | 45.03% | 46.54% | 45.62% | 43.52% | 43.95% | 44.07% | 46.58% | 46.27% | 47.99% | - |
Gross Profit | 1.19B▲ 0% | 1.22B▲ 3.1% | 1.26B▲ 2.7% | 1.44B▲ 14.4% | 1.64B▲ 13.9% | 1.57B▼ 4.3% | 1.43B▼ 9.0% | 1.38B▼ 3.4% | 1.34B▼ 2.6% | 1.34B▲ 0% |
Gross Margin % | 54.97% | 53.46% | 54.38% | 56.48% | 56.05% | 55.93% | 53.42% | 53.73% | 52.01% | 51.87% |
Gross Profit Growth % | 4.33% | 3.11% | 2.67% | 14.39% | 13.92% | -4.32% | -8.96% | -3.37% | -2.56% | - |
Operating Expenses | 1.06B | 1.03B | 1.03B | 1.02B | 1.14B | 1.08B | 1.09B | 1.11B | 1.08B | 1.1B |
OpEx % of Revenue | 49.04% | 45.08% | 44.44% | 39.93% | 38.93% | 38.71% | 40.77% | 43.25% | 41.71% | - |
Selling, General & Admin | 808.94M | 833.29M | 824.63M | 798.8M | 877.12M | 827.83M | 841.7M | 814M | 819.9M | 843.5M |
SG&A % of Revenue | 37.45% | 36.39% | 35.67% | 31.38% | 30.01% | 29.54% | 31.51% | 31.72% | 31.74% | - |
Research & Development | 250.3M | 199.2M | 202.71M | 217.76M | 260.64M | 256.89M | 247.43M | 295.9M | 256.9M | 260.4M |
R&D % of Revenue | 11.59% | 8.7% | 8.77% | 8.55% | 8.92% | 9.17% | 9.26% | 11.53% | 9.95% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | 116.65M▲ 0% | -108.64M▼ 193.1% | 229.66M▲ 311.4% | 421.33M▲ 83.5% | 500.34M▲ 18.8% | 482.62M▼ 3.5% | 337.8M▼ 30.0% | 269M▼ 20.4% | 270.5M▲ 0.6% | 239.5M▲ 0% |
Operating Margin % | 5.4% | -4.74% | 9.93% | 16.55% | 17.12% | 17.22% | 12.65% | 10.48% | 10.47% | 9.25% |
Operating Income Growth % | 119.29% | -193.13% | 311.39% | 83.46% | 18.75% | -3.54% | -30.01% | -20.37% | 0.56% | - |
EBITDA | 265.35M | 29.46M | 404.16M | 559.93M | 637.94M | 659.82M | 483.7M | 420.6M | 475.9M | -314.9M |
EBITDA Margin % | 12.28% | 1.29% | 17.48% | 22% | 21.83% | 23.55% | 18.11% | 16.39% | 18.42% | -12.16% |
EBITDA Growth % | 35.32% | -88.9% | 1271.94% | 38.54% | 13.93% | 3.43% | -26.69% | -13.04% | 13.15% | -173.05% |
D&A (Non-Cash Add-back) | 148.7M | 138.1M | 174.5M | 138.6M | 137.6M | 177.2M | 145.9M | 151.6M | 205.4M | 157.2M |
EBIT | 120.82M | 536.62M | 2.28B | 4.94B | 5.45B | -4.67B | -800.66M | -2.29B | 270.5M | -122.6M |
Net Interest Income | -3.91M | 2.64M | 7.08M | -3.66M | 17.35M | 19.89M | 51.46M | 33.1M | 46.5M | 10.1M |
Interest Income | 19.1M | 26.6M | 30.5M | 18.2M | 18.9M | 58M | 100.9M | 82M | 95.5M | 59.4M |
Interest Expense | 23.01M | 23.96M | 23.42M | 21.86M | 1.55M | 38.11M | 49.44M | 48.9M | 49M | 49.3M |
Other Income/Expense | -15.35M | 319.39M | 2.03B | 4.5B | 4.95B | -5.19B | -1.19B | -2.61B | 725M | -17.2M |
Pretax Income | 97.81M▲ 0% | 507.36M▲ 418.7% | 2.26B▲ 345.7% | 4.92B▲ 117.5% | 5.45B▲ 10.8% | -4.7B▼ 186.3% | -850.1M▲ 81.9% | -2.34B▼ 175.6% | 995.5M▲ 142.5% | 222.3M▲ 0% |
Pretax Margin % | 4.53% | 22.15% | 97.81% | 193.19% | 186.45% | -167.87% | -31.82% | -91.27% | 38.54% | 8.58% |
Income Tax | -16.93M | 146.36M | 502.41M | 1.1B | 1.19B | -1.08B | -212.78M | -498.3M | 235.6M | 53.5M |
Effective Tax Rate % | -17.32% | 28.85% | 22.22% | 22.44% | 21.93% | 22.89% | 25.03% | 21.27% | 23.67% | 24.07% |
Net Income | 114.74M▲ 0% | 361M▲ 214.6% | 1.76B▲ 387.2% | 3.81B▲ 116.9% | 4.25B▲ 11.5% | -3.63B▼ 185.3% | -637.32M▲ 82.4% | -1.84B▼ 189.4% | 759.9M▲ 141.2% | 168.8M▲ 0% |
Net Margin % | 5.31% | 15.76% | 76.08% | 149.83% | 145.57% | -129.45% | -23.86% | -71.86% | 29.42% | 6.52% |
Net Income Growth % | 307.96% | 214.62% | 387.17% | 116.88% | 11.54% | -185.27% | 82.43% | -189.37% | 141.2% | 107.8% |
Net Income (Continuing) | 122.25M | 365.61M | 1.76B | 3.81B | 4.25B | -3.63B | -637.32M | -1.84B | 759.9M | 168.8M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 4.07▲ 0% | 11.94▲ 193.4% | 58.27▲ 388.0% | 126.20▲ 116.6% | 140.83▲ 11.6% | -121.79▼ 186.5% | -21.82▲ 82.1% | -65.36▼ 199.5% | 27.87▲ 142.6% | 6.26▲ 0% |
EPS Growth % | 362.5% | 193.37% | 388.02% | 116.58% | 11.59% | -186.48% | 82.08% | -199.54% | 142.64% | 107.97% |
EPS (Basic) | 4.12 | 12.10 | 58.93 | 127.86 | 142.61 | -121.79 | -21.82 | -65.36 | 27.87 | - |
Diluted Shares Outstanding | 30.03M | 30.23M | 30.18M | 30.16M | 30.21M | 29.79M | 29.21M | 28.21M | 27.28M | 26.96M |
Basic Shares Outstanding | 29.66M | 29.84M | 29.84M | 29.77M | 29.83M | 29.79M | 29.21M | 28.21M | 27.26M | 26.96M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BIO Balance Sheet
Bio-Rad Laboratories, Inc. (BIO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.98B | 2.02B | 2.18B | 2.14B | 1.99B | 3.16B | 3.05B | 3.03B | 2.91B | 0 |
Cash & Short-Term Investments | 754.98M | 844.8M | 1.11B | 991.12M | 869.92M | 1.79B | 1.61B | 1.66B | 1.54B | 0 |
Cash Only | 383.82M | 431.53M | 660.67M | 662.21M | 470.78M | 434.21M | 403.8M | 488.1M | 531.8M | 0 |
Short-Term Investments | 371.15M | 413.27M | 453.97M | 328.91M | 399.13M | 1.36B | 1.2B | 1.18B | 1.01B | 0 |
Accounts Receivable | 464.85M | 392.44M | 392.67M | 419.42M | 423.54M | 494.64M | 489M | 452.5M | 472.5M | 0 |
Days Sales Outstanding | 78.55 | 62.55 | 62 | 60.14 | 52.9 | 64.43 | 66.82 | 64.35 | 66.76 | 49.91 |
Inventory | 594.8M | 583.82M | 554.01M | 622.25M | 572.24M | 719.32M | 780.5M | 760M | 740.7M | 0 |
Days Inventory Outstanding | 223.18 | 199.95 | 191.73 | 205.03 | 162.61 | 212.61 | 228.95 | 233.58 | 218.1 | 170.02 |
Other Current Assets | 15.88M | 15.18M | 16.5M | 16.42M | 15.65M | 29.16M | 31.7M | 30.7M | 13.8M | 0 |
Total Non-Current Assets | 2.3B | 3.59B | 5.83B | 10.83B | 15.81B | 10.34B | 9.25B | 6.33B | 7.67B | 0 |
Property, Plant & Equipment | 493.5M | 508.69M | 701.21M | 693.51M | 716.44M | 679.55M | 723.7M | 688.6M | 709.9M | 0 |
Fixed Asset Turnover | 4.38x | 4.50x | 3.30x | 3.67x | 4.08x | 4.12x | 3.69x | 3.73x | 3.64x | 4.77x |
Goodwill | 506.1M | 219.8M | 264.1M | 291.9M | 347.3M | 406.5M | 413.6M | 410.5M | 579.8M | 0 |
Intangible Assets | 174.1M | 133.1M | 145.5M | 199.5M | 253.9M | 332.1M | 320.5M | 293.6M | 174.3M | 0 |
Long-Term Investments | 1.03B | 2.66B | 4.64B | 9.56B | 14.39B | 8.83B | 7.7B | 4.84B | 6.1B | 16.74B |
Other Non-Current Assets | 94.95M | 70.3M | 79.64M | 86.72M | 104.19M | 94.6M | 94.9M | 101.9M | 102.3M | 0 |
Total Assets | 4.27B▲ 0% | 5.61B▲ 31.3% | 8.01B▲ 42.7% | 12.97B▲ 62.0% | 17.8B▲ 37.2% | 13.5B▼ 24.1% | 12.3B▼ 8.9% | 9.36B▼ 23.9% | 10.58B▲ 12.9% | 0▲ 0% |
Asset Turnover | 0.51x | 0.41x | 0.29x | 0.20x | 0.16x | 0.21x | 0.22x | 0.27x | 0.24x | 0.34x |
Asset Growth % | 10.97% | 31.31% | 42.73% | 61.98% | 37.21% | -24.15% | -8.91% | -23.86% | 12.95% | -90.18% |
Total Current Liabilities | 502.7M | 450.8M | 905.5M | 631.54M | 680.94M | 568.71M | 522.8M | 467.8M | 517M | 917M |
Accounts Payable | 135.18M | 122.45M | 107.01M | 139.45M | 141.94M | 135.04M | 144.6M | 122.3M | 129M | 133.1M |
Days Payables Outstanding | 50.72 | 41.94 | 37.04 | 45.95 | 40.34 | 39.91 | 42.42 | 37.59 | 37.98 | 38.81 |
Short-Term Debt | 420K | 493K | 425.7M | 1.3M | 489K | 465K | 500K | 1.2M | 37.9M | 436.7M |
Deferred Revenue (Current) | 28.23M | 26.94M | 33.73M | 42.47M | 50.85M | 52.21M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 127.29M | 101.22M | 86.81M | 131.1M | 127.94M | 117.44M | 161.6M | 147.2M | 141.2M | 347.2M |
Current Ratio | 3.93x | 4.49x | 2.41x | 3.39x | 2.92x | 5.55x | 5.83x | 6.48x | 5.62x | 0.00x |
Quick Ratio | 2.75x | 3.19x | 1.80x | 2.40x | 2.08x | 4.29x | 4.34x | 4.85x | 4.19x | 0.00x |
Cash Conversion Cycle | 251.01 | 220.56 | 216.7 | 219.22 | 175.17 | 237.12 | 253.35 | 260.35 | 246.88 | 181.12 |
Total Non-Current Liabilities | 840.07M | 1.14B | 1.35B | 2.46B | 3.43B | 3.32B | 3.04B | 2.33B | 2.61B | 2.02B |
Long-Term Debt | 434.58M | 438.94M | 2.4M | 1.3M | 10.51M | 1.2B | 1.2B | 1.2B | 1.34B | 138.6M |
Capital Lease Obligations | 0 | 0 | 187.22M | 186.13M | 175.94M | 153.6M | 165.5M | 131.4M | 154.4M | 483.8M |
Deferred Tax Liabilities | 222.21M | 553.24M | 997.79M | 2.08B | 3.06B | 1.77B | 1.48B | 818M | 1.06B | 3.77B |
Other Non-Current Liabilities | 183.28M | 147.77M | 160.9M | 196.93M | 182.19M | 195.93M | 195M | 177.2M | 53.4M | 1B |
Total Liabilities | 1.34B | 1.59B | 2.25B | 3.09B | 4.11B | 3.89B | 3.56B | 2.79B | 3.12B | 2.94B |
Total Debt | 435M | 439.43M | 651.18M | 225.74M | 223.38M | 1.39B | 1.41B | 1.37B | 1.53B | 575.3M |
Net Debt | 51.18M | 7.9M | -9.49M | -436.47M | -247.41M | 953.88M | 1B | 886.6M | 999.2M | 575.3M |
Debt / Equity | 0.15x | 0.11x | 0.11x | 0.02x | 0.02x | 0.14x | 0.16x | 0.21x | 0.21x | 0.08x |
Debt / EBITDA | 1.64x | 14.92x | 1.61x | 0.40x | 0.35x | 2.10x | 2.91x | 3.27x | 3.22x | -1.83x |
Net Debt / EBITDA | 0.19x | 0.27x | -0.02x | -0.78x | -0.39x | 1.45x | 2.07x | 2.11x | 2.10x | -1.83x |
Interest Coverage | 5.25x | 22.39x | 97.56x | 225.97x | 3514.25x | -122.43x | -16.20x | -46.90x | 5.52x | -2.49x |
Total Equity | 2.93B▲ 0% | 4.02B▲ 37.2% | 5.76B▲ 43.1% | 9.88B▲ 71.7% | 13.69B▲ 38.5% | 9.62B▼ 29.7% | 8.74B▼ 9.1% | 6.57B▼ 24.8% | 7.45B▲ 13.5% | 6.85B▲ 0% |
Equity Growth % | 13.61% | 37.2% | 43.15% | 71.67% | 38.52% | -29.74% | -9.09% | -24.85% | 13.46% | 11.17% |
Book Value per Share | 97.56 | 133.00 | 190.67 | 327.58 | 453.03 | 322.82 | 299.26 | 232.84 | 273.22 | 254.15 |
Total Shareholders' Equity | 2.93B | 4.02B | 5.76B | 9.88B | 13.69B | 9.62B | 8.74B | 6.57B | 7.45B | 6.85B |
Common Stock | 3K | 3K | 3K | 3K | 3K | 3K | 0 | 0 | 0 | 0 |
Retained Earnings | 1.83B | 3.72B | 5.47B | 9.27B | 13.53B | 9.9B | 9.26B | 7.42B | 8.18B | 7.65B |
Treasury Stock | -217K | -49.13M | -38.4M | -99.91M | -106.29M | -263.59M | -632.5M | -772.1M | -1.01B | 0 |
Accumulated OCI | 738.79M | -46.96M | -87.35M | 282.46M | -175.55M | -466.82M | -336M | -538.2M | -189.1M | -235.4M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BIO Cash Flow Statement
Bio-Rad Laboratories, Inc. (BIO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 104.14M | 285.49M | 457.9M | 584.97M | 669.46M | 194.45M | 374.94M | 455.2M | 532.2M | 510.4M |
Operating CF Margin % | 4.82% | 12.47% | 19.81% | 22.98% | 22.91% | 6.94% | 14.04% | 17.74% | 20.6% | - |
Operating CF Growth % | -51.8% | 174.15% | 60.39% | 27.75% | 14.44% | -70.95% | 92.83% | 21.41% | 16.92% | 9.24% |
Net Income | 122.2M | 365.6M | 1.76B | 3.81B | 4.25B | -3.63B | -637.3M | -1.84B | 759.9M | 168.8M |
Depreciation & Amortization | 148.7M | 138.1M | 134.2M | 138.6M | 137.6M | 137.3M | 145.9M | 151.6M | 205.4M | 68.5M |
Stock-Based Compensation | 23.4M | 27.8M | 35.6M | 41.6M | 51.2M | 60.9M | 61.3M | 62.3M | 0 | -15.3M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 170.5M | 101.8M |
Other Non-Cash Items | 13.54M | -323.01M | -2.03B | -4.5B | -4.92B | 5.23B | 1.24B | 2.71B | -879.2M | -94.3M |
Working Capital Changes | -203.7M | 77M | 555.9M | 1.09B | 1.14B | -1.61B | -432.8M | -620.8M | 275.6M | 202.7M |
Change in Receivables | -64.1M | 59.7M | 1.6M | -15M | -20.4M | -87.4M | 11.4M | 16.2M | 19.6M | -29.1M |
Change in Inventory | -47.7M | -12.9M | 24.2M | -52.1M | 46.1M | -158.8M | -46.3M | 8.5M | 68.9M | 83.1M |
Change in Payables | 7.8M | -45.6M | 10.6M | 124.7M | 69.9M | -94.2M | -51.8M | -40.9M | -100K | -64.4M |
Cash from Investing | -175.57M | -186.98M | -208.89M | -69.89M | -797.38M | -1.21B | 20.21M | -160.2M | -189.7M | -285.8M |
Capital Expenditures | -115.13M | -129.83M | -98.53M | -108.56M | -133.75M | -112.78M | -156.68M | -165.6M | -157.6M | -153.2M |
CapEx % of Revenue | 5.33% | 5.67% | 4.26% | 4.26% | 4.58% | 4.02% | 5.87% | 6.45% | 6.1% | 5.92% |
Acquisitions | 0 | 6.96M | -79.39M | -84.42M | -125.52M | -99.39M | 2.5M | 0 | -218.4M | -218.4M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -914K | 4.32M | 8.95M | 3.48M | -453.39M | -1.21M | 211K | -23.3M | 793.6M | 793.7M |
Cash from Financing | 341K | -48.68M | -22.76M | -523.04M | -55.43M | 973.58M | -425.65M | -218.8M | -283.2M | -229.5M |
Debt Issued (Net) | -352K | -2.96M | -643K | -426.94M | -3.02M | 1.19B | -467K | -400K | -500K | -700K |
Equity Issued (Net) | -2.92M | -48.91M | -28M | -100M | -50M | -215.68M | -428.73M | -203.6M | -279.7M | -182.1M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -33.3M |
Share Repurchases | -2.92M | -48.91M | -28M | -100M | -50M | -215.68M | -428.73M | -203.6M | -295.5M | -241.4M |
Other Financing | 3.61M | 3.19M | 5.88M | 3.9M | -2.41M | 3.54M | 3.55M | -14.8M | -3M | -13.4M |
Net Change in Cash | -72.19M▲ 0% | 49.18M▲ 168.1% | 228.49M▲ 364.6% | 4.46M▼ 98.0% | -195.98M▼ 4490.3% | -36.59M▲ 81.3% | -30.18M▲ 17.5% | 85.4M▲ 383.0% | 40.3M▼ 52.8% | -16.1M▲ 0% |
Free Cash Flow | -10.99M▲ 0% | 155.67M▲ 1516.4% | 359.37M▲ 130.9% | 476.41M▲ 32.6% | 535.72M▲ 12.4% | 80.29M▼ 85.0% | 218.26M▲ 171.8% | 266.2M▲ 22.0% | 374.6M▲ 40.7% | 357.2M▲ 0% |
FCF Margin % | -0.51% | 6.8% | 15.55% | 18.71% | 18.33% | 2.87% | 8.17% | 10.37% | 14.5% | 13.79% |
FCF Growth % | -114.75% | 1516.43% | 130.86% | 32.57% | 12.45% | -85.01% | 171.84% | 21.96% | 40.72% | 7.56% |
FCF per Share | -0.37 | 5.15 | 11.91 | 15.80 | 17.73 | 2.70 | 7.47 | 9.44 | 13.73 | 13.25 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.79x | 0.26x | 0.15x | 0.16x | -0.05x | -0.59x | -0.25x | 0.70x | 2.12x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BIO Key Ratios
Bio-Rad Laboratories, Inc. (BIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 4.17% | 10.39% | 35.98% | 48.79% | 36.11% | -31.14% | -6.94% | -24.09% | 10.84% | 2.4% |
Return on Invested Capital (ROIC) | 3.16% | -2.32% | 3.52% | 4.16% | 3.28% | 3.02% | 2.49% | 2.35% | 2.55% | 2.26% |
Gross Margin | 54.97% | 53.46% | 54.38% | 56.48% | 56.05% | 55.93% | 53.42% | 53.73% | 52.01% | 51.87% |
Net Margin | 5.31% | 15.76% | 76.08% | 149.83% | 145.57% | -129.45% | -23.86% | -71.86% | 29.42% | 6.52% |
Debt / Equity | 0.15x | 0.11x | 0.11x | 0.02x | 0.02x | 0.14x | 0.16x | 0.21x | 0.21x | 0.08x |
Interest Coverage | 5.25x | 22.39x | 97.56x | 225.97x | 3514.25x | -122.43x | -16.20x | -46.90x | 5.52x | -2.49x |
FCF Conversion | 0.91x | 0.79x | 0.26x | 0.15x | 0.16x | -0.05x | -0.59x | -0.25x | 0.70x | 2.12x |
Revenue Growth | 4.45% | 6.02% | 0.94% | 10.12% | 14.81% | -4.12% | -4.67% | -3.92% | 0.65% | 1.92% |
Related:BIO Dividend History·BIO Revenue History·BIO Price History·BIO P/E History·BIO Financial Ratios·BIO Institutional Holders
BIO SEC Filings & Documents
Bio-Rad Laboratories, Inc. (BIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
BIO Frequently Asked Questions
Bio-Rad Laboratories, Inc. (BIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bio-Rad Laboratories, Inc. (BIO) reported $2.59B in revenue for fiscal year 2025. This represents a 518% increase from $418.8M in 1996.
Bio-Rad Laboratories, Inc. (BIO) grew revenue by 0.7% over the past year. Growth has been modest.
Yes, Bio-Rad Laboratories, Inc. (BIO) is profitable, generating $168.8M in net income for fiscal year 2025 (29.4% net margin).
Dividend & Returns
Bio-Rad Laboratories, Inc. (BIO) has a return on equity (ROE) of 10.8%. This is reasonable for most industries.
Bio-Rad Laboratories, Inc. (BIO) generated $357.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.